Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565223 | 1.00 | APP (0.41) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL17980283 | 1.00 | APP (0.41) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL21081110 | 1.00 | APP (0.41) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL18022628 | 0.91 | APP (0.42) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL24080179 | 0.87 | GPR119 (0.41) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL18353813 | 0.87 | GPR119 (0.42) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL28897864 | 0.87 | GPR119 (0.41) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL17979924 | 0.87 | GPR119 (0.41) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL17980038 | 0.85 | GPR119 (0.37) | APPHTR1AADRA2ADRD2ADRA2B | |
| SCHEMBL25400278 | 0.85 | GPR119 (0.37) | APPHTR1AADRA2ADRD2ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4046995-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3256466-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2016130796-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016130796-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001987-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | APP 1760/4885HTR1A 29/4885ADRA2A 690/4885 |
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | APP 1760/4885HTR1A 29/4885ADRA2A 690/4885 |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | APP 1760/4885HTR1A 29/4885ADRA2A 690/4885 |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | APP 1760/4885HTR1A 29/4885ADRA2A 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.